|
English
|
正體中文
|
简体中文
|
2831143
|
|
???header.visitor??? :
33117743
???header.onlineuser??? :
731
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"moore m"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2023-11 |
ILLUMINATE: Efficacy and safety of durvalumab-tremelimumab and chemotherapy in EGFR mutant NSCLC following progression on EGFR inhibitors
|
Lee, C;Liao, BC;Subramaniam, S;Chiu, CH;Mersiades, A;Ho, CC;Brown, C;Lai, CL;Hughes, BGM;Yang, TY;O'Byrne, K;Luo, YH;Yip, S;Ho, CL;Bray, V;Su, WC;Moore, M;Feng, WL;Bai, YY;Stockler, M;Solomon, B;John, T;Yang, JCH |
| 臺大學術典藏 |
2020-04-10T12:51:07Z |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study
|
Van Cutsem E.; Li C.-P.; Nowara E.; Aprile G.; Moore M.; Federowicz I.; Van Laethem J.-L.; Chiun Hsu; Tham C.K.; Stemmer S.M.; Lipp R.; Zeaiter A.; Fittipaldo A.; Csutor Z.; Klughammer B.; Meng X.; Ciuleanu T. |
| 臺大學術典藏 |
2014 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study
|
Ciuleanu T.; Klughammer B.; Meng X.; Csutor Z.; Fittipaldo A.; Zeaiter A.; Lipp R.; Stemmer S.M.; CHIUN HSU; Tham C.K.; Van Cutsem E.; Li C.-P.; Nowara E.; Aprile G.; Moore M.; Federowicz I.; Van Laethem J.-L. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
